LISATA THERAPEUTICS INC (LSTA) Fundamental Analysis & Valuation

NASDAQ:LSTA • US1280583022

Current stock price

3.13 USD
+0.01 (+0.32%)
At close:
3.22 USD
+0.09 (+2.88%)
After Hours:

This LSTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LSTA Profitability Analysis

1.1 Basic Checks

  • LSTA had negative earnings in the past year.
  • LSTA had a negative operating cash flow in the past year.
  • LSTA had negative earnings in each of the past 5 years.
  • In the past 5 years LSTA always reported negative operating cash flow.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M

1.2 Ratios

  • With a Return On Assets value of -93.47%, LSTA is not doing good in the industry: 73.84% of the companies in the same industry are doing better.
  • LSTA has a Return On Equity (-111.65%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -93.47%
ROE -111.65%
ROIC N/A
ROA(3y)-62.89%
ROA(5y)-58.26%
ROE(3y)-74.17%
ROE(5y)-66.74%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LSTA Health Analysis

2.1 Basic Checks

  • LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LSTA has been increased compared to 1 year ago.
  • Compared to 5 years ago, LSTA has more shares outstanding
  • LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • LSTA has an Altman-Z score of -41.07. This is a bad value and indicates that LSTA is not financially healthy and even has some risk of bankruptcy.
  • LSTA's Altman-Z score of -41.07 is on the low side compared to the rest of the industry. LSTA is outperformed by 91.28% of its industry peers.
  • There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.07
ROIC/WACCN/A
WACC9.45%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • LSTA has a Current Ratio of 5.76. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
  • LSTA has a Current ratio of 5.76. This is in the better half of the industry: LSTA outperforms 60.47% of its industry peers.
  • A Quick Ratio of 5.76 indicates that LSTA has no problem at all paying its short term obligations.
  • LSTA has a Quick ratio of 5.76. This is in the better half of the industry: LSTA outperforms 61.05% of its industry peers.
Industry RankSector Rank
Current Ratio 5.76
Quick Ratio 5.76
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LSTA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.31% over the past year.
  • Looking at the last year, LSTA shows a very negative growth in Revenue. The Revenue has decreased by -83.00% in the last year.
EPS 1Y (TTM)20.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.88%
Revenue 1Y (TTM)-83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90%

3.2 Future

  • Based on estimates for the next years, LSTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.43% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.71%
EPS Next 2Y31%
EPS Next 3Y16.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2022 2024 2025 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. LSTA Valuation Analysis

4.1 Price/Earnings Ratio

  • LSTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • LSTA's earnings are expected to grow with 16.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31%
EPS Next 3Y16.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LSTA Dividend Analysis

5.1 Amount

  • No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LSTA Fundamentals: All Metrics, Ratios and Statistics

LISATA THERAPEUTICS INC

NASDAQ:LSTA (5/1/2026, 8:00:01 PM)

After market: 3.22 +0.09 (+2.88%)

3.13

+0.01 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.04
Industry Growth13.66
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners7.86%
Inst Owner Change14.01%
Ins Owners9.51%
Ins Owner Change22.8%
Market Cap28.26M
Revenue(TTM)170.00K
Net Income(TTM)-16.59M
Analysts82.22
Price Target11.56 (269.33%)
Short Float %0.73%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 166.26
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0.02
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -93.47%
ROE -111.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.89%
ROA(5y)-58.26%
ROE(3y)-74.17%
ROE(5y)-66.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.18%
Cap/Sales 16.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.76
Quick Ratio 5.76
Altman-Z -41.07
F-Score2
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.88%
EPS Next Y58.71%
EPS Next 2Y31%
EPS Next 3Y16.43%
EPS Next 5YN/A
Revenue 1Y (TTM)-83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.84%
EBIT Next 3Y-4.55%
EBIT Next 5YN/A
FCF growth 1Y17.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.6%
OCF growth 3YN/A
OCF growth 5YN/A

LISATA THERAPEUTICS INC / LSTA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LISATA THERAPEUTICS INC (LSTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LSTA.


What is the valuation status for LSTA stock?

ChartMill assigns a valuation rating of 0 / 10 to LISATA THERAPEUTICS INC (LSTA). This can be considered as Overvalued.


What is the profitability of LSTA stock?

LISATA THERAPEUTICS INC (LSTA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for LSTA stock?

The Earnings per Share (EPS) of LISATA THERAPEUTICS INC (LSTA) is expected to grow by 58.71% in the next year.